GLP Watchdog

GoodRx vs Midi Health

Neither GoodRx nor Midi Health has an FDA warning letter on record. Midi Health lists its visit fee, and the medication is billed separately, so it has no all-in monthly price to set against another seller's. GoodRx starts at $149 a month for Foundayo (orforglipron) pill.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Midi Health

GoodRx logo

GoodRx

7.8/10

Midi Health logo

Midi Health

4.9/10

FDA warning letters
None on record
None on record
Pharmacy
Brand-name only; no compounding
  • Precision Compounding Pharmacytype not stated
Lowest standing price
$149/moFoundayo (orforglipron) pill
No GLP-1 price published
States
48 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit GoodRx
Visit Midi Health

Neither GoodRx nor Midi Health pays us. Links to them earn nothing. Scores: GoodRx 7.8, Midi Health 4.9. How we are paid

What the record shows

  1. 01

    Neither GoodRx nor Midi Health has an FDA warning letter on record.

  2. 02

    Midi Health names Precision Compounding Pharmacy. GoodRx sells brand-name medication only.

  3. 03

    Midi Health lists its visit fee, and the medication is billed separately, so it has no all-in monthly price to set against another seller's. GoodRx starts at $149 a month for Foundayo (orforglipron) pill.

  4. 04

    Only GoodRx lists a price for brand-name tirzepatide pen and Foundayo (orforglipron) pill.

  5. 05

    Midi Health covers two states GoodRx does not.

  6. 06

    GoodRx states you can cancel at any time; Midi Health does not state its cancellation terms.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Midi Health

Brand-name tirzepatide pen

$299/mo

$3,588 a year

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Cancel any time
Yes, stated
Not stated
Minimum term
None
Not stated
Refunds
Services and medication are generally non-refundable
Payments are non-refundable; an order may be canceled before shipment at Midi's discretion

Read off each seller’s own pages. GoodRx: October 30, 2026. Midi Health: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • Sells brand-name tirzepatide pen and Foundayo (orforglipron) pill, which Midi Health does not price
  • States you can cancel at any time
Visit GoodRx

The case for Midi Health

4.9/10

The record gives Midi Health no edge on this pair.

  • Publishes no GLP-1 price
Visit Midi Health

Scores

GoodRx 7.8 · Midi Health 4.9 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

5.0A
vs
B
2.5

Trust & Safety15%

6.0A
vs
B
6.5

Accessibility10%

9.7A
vs
B
10.0

Support10%

5.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Midi Health: questions

Neither GoodRx nor Midi Health has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Midi Health names Precision Compounding Pharmacy. GoodRx sells brand-name medication only.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Midi Health does not state its cancellation terms.
Neither GoodRx nor Midi Health pays us. Links to them earn nothing. Scores: GoodRx 7.8, Midi Health 4.9.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks